These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 8605634)
1. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. Can J Cardiol; 1996 Feb; 12(2):127-37. PubMed ID: 8605634 [TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial. Sumner G; Salehian O; Yi Q; Healey J; Mathew J; Al-Merri K; Al-Nemer K; Mann JF; Dagenais G; Lonn E; J Cardiovasc Electrophysiol; 2009 Jul; 20(7):781-7. PubMed ID: 19298567 [TBL] [Abstract][Full Text] [Related]
3. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Gerstein HC Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991 [TBL] [Abstract][Full Text] [Related]
4. The HOPE Study (Heart Outcomes Prevention Evaluation). Sleight P J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789 [TBL] [Abstract][Full Text] [Related]
5. Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding? Mancini GB; Stewart DJ Can J Cardiol; 2001 May; 17 Suppl A():15A-7A. PubMed ID: 11381289 [TBL] [Abstract][Full Text] [Related]
6. Diabetes and the HOPE study: implications for macrovascular and microvascular disease. Gerstein HC Int J Clin Pract Suppl; 2001 Jan; (117):8-12. PubMed ID: 11715357 [TBL] [Abstract][Full Text] [Related]
7. Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial. Dagenais GR; Yi Q; Lonn E; Sleight P; Ostergren J; Yusuf S; Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):75-81. PubMed ID: 15703510 [TBL] [Abstract][Full Text] [Related]
8. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. Teo KK; Mitchell LB; Pogue J; Bosch J; Dagenais G; Yusuf S; Circulation; 2004 Sep; 110(11):1413-7. PubMed ID: 15353497 [TBL] [Abstract][Full Text] [Related]
9. Future perspectives and implications. Sleight P Int J Clin Pract Suppl; 2001 Jan; (117):22-3. PubMed ID: 11715355 [TBL] [Abstract][Full Text] [Related]
10. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. McQueen MJ; Lonn E; Gerstein HC; Bosch J; Yusuf S Scand J Clin Lab Invest Suppl; 2005; 240():143-56. PubMed ID: 16112972 [TBL] [Abstract][Full Text] [Related]
11. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Bosch J; Lonn E; Pogue J; Arnold JM; Dagenais GR; Yusuf S; Circulation; 2005 Aug; 112(9):1339-46. PubMed ID: 16129815 [TBL] [Abstract][Full Text] [Related]
12. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Blankenberg S; McQueen MJ; Smieja M; Pogue J; Balion C; Lonn E; Rupprecht HJ; Bickel C; Tiret L; Cambien F; Gerstein H; Münzel T; Yusuf S; Circulation; 2006 Jul; 114(3):201-8. PubMed ID: 16831981 [TBL] [Abstract][Full Text] [Related]
13. [The HOPE Study. What does it contribute to general practice?]. Mann J; Sleight P MMW Fortschr Med; 2000 Nov; 142(47):28-32. PubMed ID: 11143776 [TBL] [Abstract][Full Text] [Related]
14. [Ten years after publishing results from The Heart Outcomes Prevention Evaluation Study--HOPE: implications on treatment with angiotensin converting enzyme inhibitors in clinical practice]. Pocanić D Lijec Vjesn; 2011; 133(1-2):69-71. PubMed ID: 21644282 [TBL] [Abstract][Full Text] [Related]
15. Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. Gianni M; Bosch J; Pogue J; Probstfield J; Dagenais G; Yusuf S; Lonn E Eur Heart J; 2007 Jun; 28(11):1382-8. PubMed ID: 17395677 [TBL] [Abstract][Full Text] [Related]
16. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. Lüders S; Schrader J; Berger J; Unger T; Zidek W; Böhm M; Middeke M; Motz W; Lübcke C; Gansz A; Brokamp L; Schmieder RE; Trenkwalder P; Haller H; Dominiak P; J Hypertens; 2008 Jul; 26(7):1487-96. PubMed ID: 18551027 [TBL] [Abstract][Full Text] [Related]
17. What is the relevance of the HOPE study in general practice? Kennedy J; Mogensen CE; Ball SG; Castaigne AD; Commerford PJ; Distiller L; Fisher BM; Gonzalez-Jaunatey J; Nosadini R; Novials A; Ostergren J; Palma-Gámiz J; Perrone-Filardi P; Schipperheijn JJ; Senges J; Trevisan R Int J Clin Pract; 2001 Sep; 55(7):449-57. PubMed ID: 11594254 [TBL] [Abstract][Full Text] [Related]
18. Ramipril. Smith WH; Ball SG Int J Clin Pract; 2000 May; 54(4):255-60. PubMed ID: 10912316 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular protection with ace inhibitors--more HOPE for EUROPA? Boos CJ Med Sci Monit; 2004 Dec; 10(12):SR23-8. PubMed ID: 15567997 [TBL] [Abstract][Full Text] [Related]
20. [Cost-effectiveness analysis of Ramipril treatment of patients at high-risk of cardiovascular events in Spain]. Hart WM; Rubio-Terrés C; Margalet Fernández I; González Juanatey JR An Med Interna; 2002 Oct; 19(10):515-20. PubMed ID: 12481494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]